USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: ELSOHLY LABORATORIES, INC.
Address: 5 INDUSTRIAL PARK DR
OXFORD, MS 38655-
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $382,169.00 6
SBIR Phase II $1,249,917.00 3
STTR Phase I $672,841.00 6
STTR Phase II $1,759,160.00 3

Award List:

DEVELOPMENT OF A NEW DOSAGE FORM FOR LONG-TERM STUDIES OF ^9-THC

Award Year / Program / Phase: 1986 / SBIR / Phase I
Agency: HHS
Principal Investigator: M A Elsohly , Principal Investigator
Award Amount: $43,000.00

DEVELOPMENT OF A CANNABIS FINGERPRINT

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mahmoud a el sohly phd
Award Amount: $48,000.00
Abstract:
This project intends to study the feasibility of developing analytical procedures to be used for identifying the countryof origin of a given cannabis sample on the basis of its chemical profile. gas chromatography/mass spectrometry (gc/ms) will be the main technique used in the development of such… More

DEVELOPMENT OF A NEW DOSAGE FORM FOR LONG-TERM STUDIES OF ^9-THC

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency: HHS
Principal Investigator: M A Elsohly , Principal Investigator
Award Amount: $252,000.00
Abstract:
Studies in this proposal will be aimed at the preparation ofa suppository formulation of a pro-drug of delta-9-tetra- hydrocannabinol (^9-thc) and study the bioavailability of thc from this formulation as compared to i.v. administrationof both thc and its prodrug. bioavailability studies will be… More

IDENTIFY/ANALYZE THC AND COCAINE METABOLITES IN MECONIUM

Award Year / Program / Phase: 1996 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00

IDENTIFY/ANALYZE THC AND COCAINE METABOLITES IN MECONIUM

Award Year / Program / Phase: 1997 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $315,780.00

PRECLINICAL DEVELOPMENT OF A NEW DRUG FOR PCP

Award Year / Program / Phase: 1998 / STTR / Phase I
Agency: HHS
Research Institution: University of Mississippi
Principal Investigator: Clark
Award Amount: $99,886.00
RI Contact: N/A

N/A

Award Year / Program / Phase: 1999 / SBIR / Phase I
Agency: HHS
Principal Investigator: M. A. Elsohly
Award Amount: $97,353.00
Abstract:
Not Available Accurate Automation Corporation (AAC) will apply the latest knowledge in optimal control, adaptive control, and learning control to develop a state-of-the-art, adaptive, nonlinear, package for robust satellite guidance and control. The guidance module will generate an optimal… More

N/A

Award Year / Program / Phase: 2000 / STTR / Phase I
Agency: HHS
Research Institution: University of Mississippi
Principal Investigator: Clark
Award Amount: $0.00
RI Contact: N/A

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Mamoud Elsohly
Award Amount: $0.00

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase II
Agency: HHS
Principal Investigator: Mamoud Elsohly
Award Amount: $682,137.00

SYNTHESIS OF CONJUGATED METABOLITES OF BUPRENOPHINE

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Shixia Feng
Award Amount: $93,816.00
Abstract:
The development of maintenance treatment for subjects with addictive behavior is an important public health issue. Buprenorphine, a promising new drug for the treatment of opiates addition, has been widely abused since the mid-90's. Using drug testing for buprenorphine will become an important… More

Transmucosal Intra-Oral Drug Delivery System for THC

Award Year / Program / Phase: 2003 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF MISSISSIPPI
Principal Investigator: Mahmoud A. Elsohly
Award Amount: $99,986.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The overall goal of this research project is to develop an effective, hot-melt extruded "Transmucosal Matrix Patch" (TMP) as a delivery system for Delta-9-Tetrahydrocannabinol (THC). THC will be incorporated into a stable, bioadhesive drug delivery system that is… More

Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

Award Year / Program / Phase: 2006 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF MISSISSIPPI
Principal Investigator: Mahmoud A. Elsohly
Award Amount: $100,074.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): The long term objectives of this proposal are aimed at the development of new composition(s) to be used for the prophylactic treatment/prevention of poison ivy contact dermatitis in sensitive individuals. Poison ivy/poison oak and another related species poison… More

Transmucosal Intra-Oral Drug Delivery System for THC

Award Year / Program / Phase: 2008 / STTR / Phase II
Agency: HHS
Research Institution: N/A
Principal Investigator:
Award Amount: $743,609.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Delta-9-Tetrahydrocannabinol (THC), the active ingredient in the cannabis plant, has a wide range of pharmacological properties of therapeutic value. The drug has been approved by the Food and Drug Administration (FDA) (Marinol(r) soft gelatin capsules) for the… More

Compositions for Prevention/Prophylactic Treatment of Poison Ivy Dermatitis

Award Year / Program / Phase: 2009 / STTR / Phase II
Agency: HHS
Research Institution: UNIVERSITY OF MISSISSIPPI
Principal Investigator: Mahmoud A. Elsohly
Award Amount: $739,218.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Poison ivy/oak contact dermatitis is the most prevalent skin allergy in the United States, affecting gt50% of the adult population. The condition is the major cause of occupational hazard among outdoor workers in fores try, agriculture and firefighting,… More

Development of Tetrahydrocannabinol Prodrugs for Topical Treatment of Glaucoma

Award Year / Program / Phase: 2011 / STTR / Phase I
Agency: HHS
Research Institution: THE UNIVERSITY OF MISSISSIPPI
Principal Investigator: Mahmoud A. Elsohly – 662-236-2609
Award Amount: $167,381.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): Currently, FDA approved clinical applications of 9-Tetrahydrocannabinol (THC) include control of nausea and vomiting associated with chemotherapy and for appetite stimulation for AIDS patients suffering from anorexia and wasting syndrome. However, THC also… More

Orally Active Formulations of DHA Dimers for the Treatment of Infectious Diseases

Award Year / Program / Phase: 2013 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF MISSISSIPPI
Principal Investigator: Mahmoud A. Elsohly – 662-236-2609
Award Amount: $205,514.00
RI Contact:
Abstract:
DESCRIPTION (provided by applicant): The natural product artemisinin is a sesquiterpene endoperoxide with known anti-malarial activity against both chloroquine-sensitive and chloroquine-resistant strains of the parasite Plasmodium falciparum. In addition to its anti-malarial activity, artemisinin… More